We are Sorry, This Page doesn't Exist
Truist starts Instil Bio with a Buy citing efficacy in solid tumors
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Inhibrx"s INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study
Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a pre.....»»
Eli Lilly Delays New Study Starts
Eli Lilly (NYSE: LLY) shares are trading lower on Monday after the company announced it will delay most of the new study starts and pause enrollment in most of the ongoing studies amid the spread of the coronavirus. read more.....»»
Eli Lilly to delay new study starts, pause enrollment in most ongoing studies
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Eli Lilly to delay new study starts, pause enrollment in most ongoing studies
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
BioXcel Therapeutics to expand BXCL701 study into multiple advanced solid tumors
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Amgen"s KRAS Inhibitor Shows Lukewarm Response In Lung Cancer Study
Amgen, Inc. (NASDAQ: AMGN) shares were pulling back Monday following the presentation of new data on its investigational compound for solid tumors. read more.....»»
NuCana Initiates Dosing in Phase I Study for Solid Tumors
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatmen.....»»
Moderna presents data from Phase 1 study in resected, unresected solid tumors
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Nektar doses first patient in Phase 1/2 study for advanced solid tumors
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Xencor doses first patient in Phase 1 study of solid tumors candidate
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merrimack completes enrollment in Phase 2 study of NSCLC candidate MM-121
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merrimack"s String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) shares were trading at record lows Friday and were down 32.85 percent at $3.46 at the time of publication. read more.....»»
Penn researchers land $10.7M grant to study CAR-T cell therapy in solid tumors
The University of Pennsylvania's Abramson Cancer Center had received a $10.7 million grant from the National Cancer Institute to study CAR-T cells in solid tumors The five-year grant from the NCI's will support new experimental approaches in lung .....»»
Eyenovia Initiates Phase III Study for Mydriasis Candidate
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies. .....»»
Amgen Starts Phase III Enrollment for Heart Failure Drug
Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fra.....»»
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study. .....»»